{
    "clinical_study": {
        "@rank": "82108", 
        "arm_group": [
            {
                "arm_group_label": "Acriflavine, Methenamine, Methylthioninium", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo to Acriflavine, Methenamine, Methylthioninium", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy of the combination of Acriflavine\n      hydrochloride + Methenamine + Methylthioninium chloride produced by EMS S/A, using the\n      comparator Placebo, the rapid relief of symptoms in uncomplicated lower urinary tract\n      infection in women."
        }, 
        "brief_title": "Efficacy Study of Acriflavine Hydrochloride + Methenamine + Methylthioninium Chloride vs Placebo for the Rapid Relief of Symptoms Urinary Tract Infection", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Lower Urinary Tract Infection", 
        "condition_browse": {
            "mesh_term": "Urinary Tract Infections"
        }, 
        "detailed_description": {
            "textblock": "-  Open, randomized, prospective study.\n\n        -  Length of experience: 05 days.\n\n        -  04 visits (days 1, 2, 5 and 7).\n\n        -  Evaluation of the efficacy and safety of the medication.\n\n        -  Shall be assessed for symptoms during the first 24 hours as pollakiuria, cystalgia,\n           dysuria, urinary urgency and odor through the report of the patients (subjective\n           parameter) and objective evaluation through laboratory tests and urine culture Urine I,\n           comparing, after 3 days treatment, the results between the groups.\n\n        -  Shall be assessed for adverse events."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients who agree to participate by agreeing to the terms proposed in the IC;\n\n          -  Patients aged over 18 years of any ethnicity;\n\n          -  Female patients;\n\n          -  Patients with clinical diagnosis of urinary tract infection (UTI), for symptomatic\n             UTI, uncomplicated, with onset of symptoms no more than 72 hours of visit 1;\n\n          -  Women who are using an effective method of birth control (hormonal contraceptives,\n             IUDs, surgical sterilization), or who are postmenopausal, in addition to condom use\n             (mandatory).\n\n        Exclusion Criteria:\n\n          -  Patients who are febrile (axillary T \u00ba: \u2265 38 \u00b0 C), with back pain or lumbar;\n\n          -  Patients with suspected STD and / or pelvic inflammatory disease;\n\n          -  Patients with complicated clinical picture of UTI-eligible or systemic antibiotic\n             therapy intravenously;\n\n          -  Patients hospitalized and / or bedridden and / or making use of urinary probe;\n\n          -  Patients with any other infectious condition that could confound interpretation of\n             clinical response to treatment;\n\n          -  Patients who received systemic antibiotic therapy / parenteral past 30 days;\n\n          -  Patients with a history of allergy or intolerance to any known or suspected one of\n             the ingredients of the product under investigation;\n\n          -  Patients who are pregnant or during lactation, or childbearing potential and are not\n             making use of effective contraception;\n\n          -  Patients presenting with renal disease or severe liver disease, according to medical\n             history and / or laboratory;\n\n          -  Patients presenting with severe systemic disease according to the known medical\n             history;\n\n          -  Patients receiving treatment with immunosuppressants, including corticosteroids\n             within 30 days before the study began, or who are receiving immunosuppressive\n             treatments or who have congenital or acquired immunodeficiency known;\n\n          -  Patients who received antibiotic treatment, anthelmintic within 15 days prior to\n             study entry;\n\n          -  Patients unable to understand the guidelines specified in this protocol or can not\n             attend all study visits or unable to complete the log;\n\n          -  Patients with a history of alcoholism, drug abuse, psychological or emotional\n             problems that would invalidate the Deed of Consent or limit the ability of patients\n             to adhere to protocol requirements;\n\n          -  Patients with any direct, familiar or not with professionals involved in conducting\n             the study or the EMS S / A;\n\n          -  Patients with uncontrolled hypertension (blood pressure [PA] pressure> 180 mmHg or\n             diastolic BP> 100 mmHg) at randomization or clinical hypertensive urgency;\n\n          -  Patients with a prior history of abnormal hematologic, hepatic, renal or metabolic\n             functions;\n\n          -  Any finding of clinical observation (history and physical examination) that is\n             interpreted by the physician investigator as a risk to the patient's participation in\n             the study."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01657448", 
            "org_study_id": "CYSEMS0112"
        }, 
        "intervention": [
            {
                "arm_group_label": "Acriflavine, Methenamine, Methylthioninium", 
                "description": "\u2022 Ingesting two (02) drives the drug with a glass of water, 8 by 8 hours for 3 days", 
                "intervention_name": "Acriflavine hydrochloride, Methenamine, Methylthioninium chloride", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo to Acriflavine, Methenamine, Methylthioninium", 
                "description": "\u2022 Ingesting two (02) drives the drug with a glass of water, 8 by 8 hours for 3 days", 
                "intervention_name": "Placebo to Acriflavine hydrochloride, Methenamine, Methylthioninium chloride", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acriflavine", 
                "Methenamine hippurate", 
                "Methenamine", 
                "Methylene Blue"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Urinary infection", 
        "lastchanged_date": "August 15, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Campinas", 
                    "country": "Brazil", 
                    "state": "S\u00e3o Paulo", 
                    "zip": "13.087-567"
                }, 
                "name": "CAEP - Centro Avan\u00e7ado de Estudos e Pesquisa"
            }, 
            "investigator": {
                "last_name": "Ulisses Magalh\u00e3es Antunes da Rocha, Md", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Parallel Study, Double-blind, Randomized, to Evaluate the Efficacy of the Combination of Drug Versus Placebo of Drug for the Rapid Relief of Symptoms of Uncomplicated Lower Urinary Tract Infection in Women", 
        "overall_contact": {
            "email": "felipe.pinho@ems.com.br", 
            "last_name": "FELIPE PINHO, MD", 
            "phone": "+ 55 19 9212 7964"
        }, 
        "overall_official": {
            "affiliation": "CAEP - Centro Avan\u00e7ado de Estudos e Pesquisa", 
            "last_name": "Ulisses Magalh\u00e3es Antunes da Rocha, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Health Surveillance Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Symptoms will be assessed during the first 24 hours as pollakiuria, cystalgia, dysuria, urinary urgency and odor through the report of the patient (subjective parameter) and objective evaluation through laboratory tests and urine culture Urine I, comparing, after 3 days treatment, the results between groups.", 
            "measure": "Efficacy of treatment in the rapid relief of symptoms in uncomplicated lower urinary tract infection", 
            "safety_issue": "No", 
            "time_frame": "3 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01657448"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To assess the safety of the study medication on the occurrence, type, intensity and frequency of adverse reactions during the treatment period.", 
            "measure": "Safety of the study medication", 
            "safety_issue": "Yes", 
            "time_frame": "5 days"
        }, 
        "source": "EMS", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "EMS", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}